Literature DB >> 11591795

Contribution of anaphylatoxin C5a to late airway responses after repeated exposure of antigen to allergic rats.

M Abe1, K Shibata, H Akatsu, N Shimizu, N Sakata, T Katsuragi, H Okada.   

Abstract

We attempted to elucidate the contribution of complement to allergic asthma. Rat sensitized to OVA received repeated intratracheal exposures to OVA for up to 3 consecutive days, and pulmonary resistance was then estimated for up to 6 h after the last exposure. Whereas the immediate airway response (IAR) in terms of R(L) tended to decrease in proportion to the number of OVA exposures, late airway response (LAR) became prominent only after three. Although premedication with two kinds of complement inhibitors, soluble complement receptor type 1 (sCR1) or nafamostat mesylate, resulted in inhibition of the IAR after either a single or a double exposure, the LAR was inhibited after the triple. Premedication with a C5a receptor antagonist (C5aRA) before every exposure to OVA also inhibited the LAR after three. Repeated OVA exposure resulted in eosinophil and neutrophil infiltration into the bronchial submucosa which was suppressed by premedication with sCR1 or C5aRA. Up-regulation of C5aR mRNA was shown in lungs after triple OVA exposure, but almost no up-regulation of C3aR. Pretreatment with sCR1 or C5aRA suppressed the up-regulation of C5aR expression as well as cytokine messages in the lungs. The suppression of LAR by pretreatment with sCR1 was reversed by intratracheal instillation of rat C5a desArg the action of which was inhibited by C5aRA. In contrast, rat C3a desArg or cytokine-induced neutrophil chemoattractant-1 induced cellular infiltration into the bronchial submucosa by costimulation with OVA, but these had no influence on the LAR. These differences might be explained by the fact that costimulation with OVA and C5a synergistically potentiated IAR, whereas that with OVA and either C3a or cytokine-induced neutrophil chemoattractant-1 did not. C5a generated by Ag-Ab complexes helps in the production of cytokines and contributes to the LAR after repeated exposure to Ag.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11591795     DOI: 10.4049/jimmunol.167.8.4651

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  21 in total

1.  An anti-coagulation agent Futhan preferentially targets GABA(A) receptors in lungepithelia: implication in treating asthma.

Authors:  Xuanmao Chen; Minghua Li; Zhi-Gang Xiong; Beverley A Orser; John F Macdonald; Wei-Yang Lu
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2011-11-15

2.  A protective role for the fifth complement component (c5) in allergic airway disease.

Authors:  Scott M Drouin; Meenal Sinha; Georgia Sfyroera; John D Lambris; Rick A Wetsel
Journal:  Am J Respir Crit Care Med       Date:  2006-01-26       Impact factor: 21.405

Review 3.  Complement activation pathways: a bridge between innate and adaptive immune responses in asthma.

Authors:  Marsha Wills-Karp
Journal:  Proc Am Thorac Soc       Date:  2007-07

Review 4.  The role of the anaphylatoxins in health and disease.

Authors:  Andreas Klos; Andrea J Tenner; Kay-Ole Johswich; Rahasson R Ager; Edimara S Reis; Jörg Köhl
Journal:  Mol Immunol       Date:  2009-05-28       Impact factor: 4.407

5.  Treatment with the C5a receptor/CD88 antagonist PMX205 reduces inflammation in a murine model of allergic asthma.

Authors:  Elizabeth B Staab; Sam D Sanderson; Sandra M Wells; Jill A Poole
Journal:  Int Immunopharmacol       Date:  2014-05-21       Impact factor: 4.932

Review 6.  Molecular basis for downregulation of C5a-mediated inflammation by IgG1 immune complexes in allergy and asthma.

Authors:  Manoj Kumar Pandey
Journal:  Curr Allergy Asthma Rep       Date:  2013-12       Impact factor: 4.806

Review 7.  The role of complement in the diagnosis and management of allergic rhinitis and allergic asthma.

Authors:  Yves Laumonnier; Inken Schmudde; Jörg Köhl
Journal:  Curr Allergy Asthma Rep       Date:  2011-04       Impact factor: 4.806

8.  Role of C5 in the development of airway inflammation, airway hyperresponsiveness, and ongoing airway response.

Authors:  Tao Peng; Liming Hao; Joseph A Madri; Xiao Su; Jack A Elias; Gregory L Stahl; Stephen Squinto; Yi Wang
Journal:  J Clin Invest       Date:  2005-05-12       Impact factor: 14.808

Review 9.  Anaphylatoxins: their role in bacterial infection and inflammation.

Authors:  Pieter-Jan Haas; Jos van Strijp
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

10.  A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma.

Authors:  Jörg Köhl; Ralf Baelder; Ian P Lewkowich; Manoj K Pandey; Heiko Hawlisch; Lihua Wang; Jennifer Best; Nancy S Herman; Alyssa A Sproles; Jörg Zwirner; Jeffrey A Whitsett; Craig Gerard; Georgia Sfyroera; John D Lambris; Marsha Wills-Karp
Journal:  J Clin Invest       Date:  2006-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.